- Title: Subtitle
- A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic lymphocytic leukemia (CLL)
- Creators
- Nandita Bose - ProThera BiologicsClive Zent - University of RochesterGeorge J. Weiner - University of IowaBetsy LaPlant - Mayo Clinic in FloridaNadine Ottoson - ProThera BiologicsSteven Leonardo - ProThera BiologicsAdria Jonas - ProThera BiologicsRichard Dale Huhn - ProThera BiologicsAda H. Braun - ProThera BiologicsStephen Maxted Ansell - Mayo Clinic Rochester, MN
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.33(15_suppl), pp.7078-7078
- DOI
- 10.1200/jco.2015.33.15_suppl.7078
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984363456902771
Abstract
A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic lymphocytic leukemia (CLL)
Journal of clinical oncology, Vol.33(15_suppl), pp.7078-7078
05/20/2015
DOI: 10.1200/jco.2015.33.15_suppl.7078
Details
Metrics
8 Record Views